Postoperative pain management is concerned with methods or techniques for reducing pain in people following surgery. Patients’ stays in hospitals are lengthened as a result of the pain, and they are subjected to physical and psychological stress. Postoperative pain management is a type of treatment focused at easing patients’ discomfort following surgery. During the forecasted period of 2017-2023, the global Post Operative Pain Management Market Trends was predicted to increase at a CAGR of 5.4 percent.
The most significant aspect of a patient’s treatment is post-operative pain management, as it aids in patient comfort, reduces the risk of pulmonary, cardiac, and neuropathic pain problems, and lowers the expense of hospitalization. The majority of this treatment consists of analgesics, which work on multiple mechanisms to reduce pain. The market is expected to develop due to an increase in the number of surgeries and increased need for pain management treatments. The market for postoperative pain management is predicted to rise in response to the growing population and increased awareness about surgical treatments for cancer and other chronic conditions such as chronic obstructive pulmonary disease (COPD).
As a result, the changing healthcare landscape and increased knowledge of postsurgical pain and trauma are predicted to raise awareness of postoperative pain management and, as a result, drive global demand for postoperative pain management. Breast cancer removal operations, such as mastectomy or lumpectomy, necessitate a high dose of postoperative pain relievers. Another factor projected to drive the growth of the postoperative pain management market is the rising prevalence of cancer. The expansion of the postoperative pain management market is being influenced by changing lifestyle preferences and choices such as aesthetic reconstruction and plastic surgery. Producers’ ongoing attempts to create novel non-opioid medications for the worldwide postoperative pain management market are expected to stimulate rivalry among postoperative pain management drug manufacturers.
Analgesics are habit-forming medications that can also harm the kidneys; this is the market’s main stumbling block. The growing number of surgical operations and surgical interventions in various illness conditions, on the other hand, is predicted to propel the postoperative pain management market to new heights.
Global post surgical pain is segmented on the basis of pain type into acute pain, moderate pain and severe pain.
On the basis of product they are segmented into non-steroidal anti-inflammatory drugs (NSAIDs), antiepileptic drugs, COX-2 inhibitors, opioids and other analgesics.
On the basis of application they are segmented into cancer pain, arthritic pain, neuropathic pain, musculoskeletal pain, migraine and others.
on the basis of target area they are back, legs, hand and arms and others.
Geographically, the America holds the highest share of the global market for post-operative pain management. The expansion of this market in America is due to an increase in the number of operations and the rising burden of chronic diseases. Increased geriatric population, strong public awareness about safe surgeries and postoperative results, and highly controlled market under constant supervision by multiple regulatory bodies are the key drivers of postoperative pain in North America. Some of the major reasons projected to fuel the growth of the postoperative pain management market in North America include well-developed healthcare infrastructure and greater healthcare spending, as well as rising cancer and chronic illness prevalence. Growing awareness of reimbursement for postoperative pain management in the United States is projected to boost postoperative pain management adoption in the global market.
Due to a well-developed healthcare infrastructure, government backing for research and development, and a large patient population, Europe is the second largest market, followed by Asia Pacific.
Oing to the rising frequency of various diseases, an aging population, and the expansion of healthcare infrastructure in this region, Asia Pacific is the market’s fastest expanding area. Because of the rising number of surgeries and the region’s leading manufacturers’ expansion plan, China is predicted to be the fastest-growing regional market for postoperative pain treatment.
Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly (U.S), Pfizer (U.S), Johnson & Johnson (U.S), Purdue Pharma (U.S), Endo Pharmaceuticals Plc. (U.S), Forest Laboratories Inc. (U.S), GlaxoSmithKline Plc. (UK), F. Hoffmann-La Roche Ltd. (Switzerland), Baxter International Inc. (US), Valeant Pharmaceuticals International Inc. (Canada)
The notable players are Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly (U.S), Pfizer (U.S), Johnson & Johnson (U.S), Purdue Pharma (U.S), Endo Pharmaceuticals Plc. (U.S), Forest Laboratories Inc. (U.S), GlaxoSmithKline Plc. (UK), F. Hoffmann-La Roche Ltd. (Switzerland), Baxter International Inc. (US), Valeant Pharmaceuticals International Inc. (Canada).
The major players are concentrating their efforts on developing novel drug delivery systems for opioid postoperative pain management medications and increasing the use of nonsteroidal anti-inflammatory medications (NSAIDs) in the treatment of postoperative pain. Some of the businesses are concentrating on creating anti-abuse medications for postoperative pain management. As a result, manufacturers’ substantial efforts are projected to fuel competition in the global postoperative pain management market.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071